GenomeWebinars

Point-of-care testing (POCT) is poised to play a transformative role in antimicrobial stewardship by enabling faster, more targeted treatment decisions. But for these tools to succeed in real-world settings — and in the market — POC tests must deliver actionable results quickly and cost-effectively, while fitting into existing clinical workflows.

This expert panel brings together clinicians, laboratory directors, and stewardship leaders to share frontline insights on how and where POC testing adds value in antimicrobial stewardship programs, what features drive clinical adoption, and what barriers still hinder implementation.

Designed for diagnostic developers, this session will highlight:

• Unmet needs in rapid resistance detection
• Considerations for integration with clinical workflows
• Usability in resource-limited and acute care settings
• Evidence thresholds for adoption and reimbursement

Join us to hear from Till Bachmann (University of Edinburgh), Birgitta Gleeson (FIND), and David Paterson (National University of Singapore, ADVANCE-ID) and gain practical guidance for designing and positioning POC tests that meet the real-world demands of antimicrobial stewardship programs.

In this conversation, global thought leaders will unpack the latest trends, breakthroughs, and future directions in NGS-based proteomics.

Christopher Mason, professor at Weill Cornell Medicine and pioneer in genomics and space biology, will share how he’s combining genomics and NGS-based proteomics to decode the molecular impact of extreme environments — championing its integration into genomics for real-time, actionable biological insights.

John Overton, VP at Regeneron Genetics Center, will share insights from the UK Biobank Pharma Proteomics Project showing how large-scale data supports benchmarking and validation and how its best practices can be adapted for other cohorts to accelerate multi-omics research.

Catharine Aquino, group leader at the Functional Genomics Center Zurich, will offer guidance on incorporating proteomics into existing NGS pipelines, showing how researchers can expand the scope and impact of their genomics work with ease.

The panel will be chaired by Cindy Lawley, Olink’s senior director of global population health, who will also add her perspective on how NGS-based proteomics can improve disease risk scoring.

Attendees will understand:

1. Recent advancements in NGS-based proteomics — what it is, how it works, and how it differs from traditional proteomics approaches or legacy techniques.
2. The essential role of proteomics in multi-omics research through real-world case studies that highlight its impact on discovery and translational science.
3. How to seamlessly integrate proteomics into an NGS pipeline, making multi-omics research more accessible and scalable.

The diagnostic, prognostic, and treatment landscape of myeloid malignancies is evolving rapidly, with genomic biomarkers increasingly defining disease diagnosis and classification. Given the continuous discovery and refinement of genomic testing requirements in the context of changing (targeted) therapies and reimbursement recommendations, there is an increasing need for genomic solutions that keep pace with clinical and regulatory demands while remaining adaptive and flexible for future advancements. 

In this webinar, Weei-Yuarn Huang, medical director for molecular diagnostics, and Hubert Tsui, head of hematological pathology, precision diagnostics and therapeutics program at the Sunnybrook Health Science Centre, will explore their recent experiences providing accurate, timely genomic results in myeloid malignancies and potential new solutions that will further enhance relevant biomarker delivery for hematology physicians and patients.